Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1801 to 1815 of 8973 results

  1. Golimumab for treating moderately to severely active ulcerative colitis in people aged 2 to 17 years [TSID11959]

    Topic prioritisation

  2. Apremilast for treating moderate to severe plaque psoriasis in people aged 6 to 17 [TSID11921]

    Topic prioritisation

  3. TAK-880 for managing primary immunodeficiency diseases in people hypersensitive to IgA [TSID11883]

    Topic prioritisation

  4. Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease in people 12 to 17 years [TSID11887]

    Topic prioritisation

  5. Subcutaneous ravulizumab for treating paroxysmal nocturnal haemoglobinuria or atypical haemolytic uraemic syndrome [TSID11820]

    Topic prioritisation

  6. CT-P39 (omalizumab biosimilar) for previously treated chronic spontaneous urticaria [TSID11832]

    Topic prioritisation

  7. Semaglutide for treating obesity-related heart failure with preserved ejection fraction [TSID11788]

    Topic prioritisation

  8. Subcutaneous efgartigmod for treating generalised myasthenia gravis [TSID11835]

    Topic prioritisation

  9. High-dose aflibercept for treating wet age-related macular degeneration [TSID10590]

    Topic prioritisation

  10. Semaglutide for treating type 2 diabetes and associated peripheral arterial disease [TSID11791]

    Topic prioritisation

  11. Sacubitril valsartan for treating chronic heart failure with reduced ejection fraction in people under 18 years [TSID10350]

    Topic prioritisation

  12. Macitentan for treating pulmonary arterial hypertension in people 1 month to 17 years [TSID11805]

    Topic prioritisation

  13. Human normal immunoglobulin for preventing infection in chronic lymphocytic leukaemia [TSID12043]

    Topic prioritisation